Precision gene therapy for liver disorders increases number of correctly repaired cells
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
Genetic mechanisms underlying Duchenne muscular dystrophy point to potential treatments
Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...
Aptose Biosciences' leukemia drug shows early promise
Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...
manilatimes15h
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML ...
Scientists Uncover Cancer’s Earliest Warning Signs – Before You’re Even Born
Van Andel Institute researchers discovered that cancer risk may be determined before birth due to distinct epigenetic states ...
FierceBiotech6d
Kura and Kyowa hail phase 2 win for leukemia drug soon heading to FDA, but hold back data
Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...
BioSpace6d
Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed
Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.